APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Recombinant DNA Vaccine

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Recombinant DNA Vaccine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

Report ID 17403136032 January 2026185 pages

Choose your research edition.

Industry ResearchRecombinant DNA Vaccine Industry Research Report 2026118 pages · $2,950 USDIndustry Growth & TrendsGlobal Recombinant DNA Vaccine Industry Growth and Trends Forecast to 203290 pages · $3,450 USDMarket StructureGlobal Recombinant DNA Vaccine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032185 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Recombinant DNA Vaccine Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal Recombinant DNA Vaccine Market Analysis and Forecast 2026-2032194 pages · $4,950 USD

Market perspective

The global Recombinant DNA Vaccine market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Recombinant DNA Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Recombinant DNA Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Recombinant DNA Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Recombinant DNA Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Recombinant DNA Vaccine include Boehringer-Ingelheim, Elanco, Indian Immunologicals, Plumbline Life Sciences, Zoties, GSK, Merck and Sanofi, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Recombinant DNA Vaccine market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Recombinant DNA Vaccine and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Recombinant DNA Vaccine sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Recombinant DNA Vaccine market size, projected growth trends, production technologies, key applications, and end-use industries.

Recombinant DNA Vaccine Segment by Company

Boehringer-Ingelheim

Elanco

Indian Immunologicals

Plumbline Life Sciences

Zoties

GSK

Merck

Sanofi

Recombinant DNA Vaccine Segment by Type

Recombinant Protein Vaccine

Gene-Based Vaccine

Recombinant DNA Vaccine Segment by Application

Human

Animal

Recombinant DNA Vaccine Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Recombinant DNA Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Recombinant DNA Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Recombinant DNA Vaccine.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Recombinant DNA Vaccine market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Recombinant DNA Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Recombinant DNA Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Recombinant DNA Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Recombinant DNA Vaccine Industry Trends Table 2. Recombinant DNA Vaccine Industry Drivers Table 3. Recombinant DNA Vaccine Industry Opportunities and Challenges Table 4. Recombinant DNA Vaccine Industry Restraints Table 5. Global Recombinant DNA Vaccine Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Recombinant DNA Vaccine Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Recombinant DNA Vaccine Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global Recombinant DNA Vaccine Sales Market Share by Manufacturers Table 9. Global Recombinant DNA Vaccine Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Recombinant DNA Vaccine Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Recombinant DNA Vaccine Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Recombinant DNA Vaccine Manufacturers, Product Type & Application Table 13. Global Recombinant DNA Vaccine Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Recombinant DNA Vaccine by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Recombinant Protein Vaccine Table 17. Major Manufacturers of Gene-Based Vaccine Table 18. Global Recombinant DNA Vaccine Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 19. Global Recombinant DNA Vaccine Sales by Type (2021-2026) & (K Units) Table 20. Global Recombinant DNA Vaccine Sales by Type (2027-2032) & (K Units) Table 21. Global Recombinant DNA Vaccine Sales Market Share by Type (2021-2026) Table 22. Global Recombinant DNA Vaccine Sales Market Share by Type (2027-2032) Table 23. Global Recombinant DNA Vaccine Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 24. Global Recombinant DNA Vaccine Revenue by Type (2021-2026) & (K Units) Table 25. Global Recombinant DNA Vaccine Revenue by Type (2027-2032) & (K Units) Table 26. Global Recombinant DNA Vaccine Revenue Market Share by Type (2021-2026) Table 27. Global Recombinant DNA Vaccine Revenue Market Share by Type (2027-2032) Table 28. Major Manufacturers of Human Table 29. Major Manufacturers of Animal Table 30. Global Recombinant DNA Vaccine Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 31. Global Recombinant DNA Vaccine Sales by Application (2021-2026) & (K Units) Table 32. Global Recombinant DNA Vaccine Sales by Application (2027-2032) & (K Units) Table 33. Global Recombinant DNA Vaccine Sales Market Share by Application (2021-2026) Table 34. Global Recombinant DNA Vaccine Sales Market Share by Application (2027-2032) Table 35. Global Recombinant DNA Vaccine Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 36. Global Recombinant DNA Vaccine Revenue by Application (2021-2026) & (K Units) Table 37. Global Recombinant DNA Vaccine Revenue by Application (2027-2032) & (K Units) Table 38. Global Recombinant DNA Vaccine Revenue Market Share by Application (2021-2026) Table 39. Global Recombinant DNA Vaccine Revenue Market Share by Application (2027-2032) Table 40. Global Recombinant DNA Vaccine Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 41. Global Recombinant DNA Vaccine Sales by Region (2021-2026) & (K Units) Table 42. Global Recombinant DNA Vaccine Sales Market Share by Region (2021-2026) Table 43. Global Recombinant DNA Vaccine Sales Forecasted by Region (2027-2032) & (K Units) Table 44. Global Recombinant DNA Vaccine Sales Forecasted Market Share by Region (2027-2032) Table 45. North America Recombinant DNA Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 46. North America Recombinant DNA Vaccine Sales by Country (2021-2026) & (K Units) Table 47. North America Recombinant DNA Vaccine Sales by Country (2027-2032) & (K Units) Table 48. Europe Recombinant DNA Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 49. Europe Recombinant DNA Vaccine Sales by Country (2021-2026) & (K Units) Table 50. Europe Recombinant DNA Vaccine Sales by Country (2027-2032) & (K Units) Table 51. Asia Pacific Recombinant DNA Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 52. Asia Pacific Recombinant DNA Vaccine Sales by Country (2021-2026) & (K Units) Table 53. Asia Pacific Recombinant DNA Vaccine Sales by Country (2027-2032) & (K Units) Table 54. South America, Middle East and Africa Recombinant DNA Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 55. South America, Middle East and Africa Recombinant DNA Vaccine Sales by Country (2021-2026) & (K Units) Table 56. South America, Middle East and Africa Recombinant DNA Vaccine Sales by Country (2027-2032) & (K Units) Table 57. Global Recombinant DNA Vaccine Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 58. Global Recombinant DNA Vaccine Revenue by Region (2021-2026) & (US$ Million) Table 59. Global Recombinant DNA Vaccine Revenue by Region (2027-2032) & (US$ Million) Table 60. Global Recombinant DNA Vaccine Revenue Market Share by Region (2021-2026) Table 61. Global Recombinant DNA Vaccine Revenue Market Share by Region (2027-2032) Table 62. Boehringer-Ingelheim Company Information Table 63. Boehringer-Ingelheim Business Overview Table 64. Boehringer-Ingelheim Recombinant DNA Vaccine Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 65. Boehringer-Ingelheim Recombinant DNA Vaccine Product Portfolio Table 66. Boehringer-Ingelheim Recent Development Table 67. Elanco Company Information Table 68. Elanco Business Overview Table 69. Elanco Recombinant DNA Vaccine Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 70. Elanco Recombinant DNA Vaccine Product Portfolio Table 71. Elanco Recent Development Table 72. Indian Immunologicals Company Information Table 73. Indian Immunologicals Business Overview Table 74. Indian Immunologicals Recombinant DNA Vaccine Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 75. Indian Immunologicals Recombinant DNA Vaccine Product Portfolio Table 76. Indian Immunologicals Recent Development Table 77. Plumbline Life Sciences Company Information Table 78. Plumbline Life Sciences Business Overview Table 79. Plumbline Life Sciences Recombinant DNA Vaccine Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 80. Plumbline Life Sciences Recombinant DNA Vaccine Product Portfolio Table 81. Plumbline Life Sciences Recent Development Table 82. Zoties Company Information Table 83. Zoties Business Overview Table 84. Zoties Recombinant DNA Vaccine Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 85. Zoties Recombinant DNA Vaccine Product Portfolio Table 86. Zoties Recent Development Table 87. GSK Company Information Table 88. GSK Business Overview Table 89. GSK Recombinant DNA Vaccine Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 90. GSK Recombinant DNA Vaccine Product Portfolio Table 91. GSK Recent Development Table 92. Merck Company Information Table 93. Merck Business Overview Table 94. Merck Recombinant DNA Vaccine Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 95. Merck Recombinant DNA Vaccine Product Portfolio Table 96. Merck Recent Development Table 97. Sanofi Company Information Table 98. Sanofi Business Overview Table 99. Sanofi Recombinant DNA Vaccine Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 100. Sanofi Recombinant DNA Vaccine Product Portfolio Table 101. Sanofi Recent Development Table 102. Key Raw Materials Table 103. Raw Materials Key Suppliers Table 104. Recombinant DNA Vaccine Distributors List Table 105. Recombinant DNA Vaccine Customers List Table 106. Research Programs/Design for This Report Table 107. Authors List of This Report Table 108. Secondary Sources Table 109. Primary Sources List of Figures Figure 1. Recombinant DNA Vaccine Product Image Figure 2. Global Recombinant DNA Vaccine Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Recombinant DNA Vaccine Market Size (2021-2032) & (US$ Million) Figure 4. Global Recombinant DNA Vaccine Sales (2021-2032) & (K Units) Figure 5. Global Recombinant DNA Vaccine Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Recombinant DNA Vaccine Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Recombinant Protein Vaccine Image Figure 9. Gene-Based Vaccine Image Figure 10. Global Recombinant DNA Vaccine Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 11. Global Recombinant DNA Vaccine Sales Market Share 2021 VS 2025 VS 2032 Figure 12. Global Recombinant DNA Vaccine Sales Market Share by Type (2021-2032) Figure 13. Global Recombinant DNA Vaccine Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 14. Global Recombinant DNA Vaccine Revenue Market Share 2021 VS 2025 VS 2032 Figure 15. Global Recombinant DNA Vaccine Revenue Market Share by Type (2021-2032) Figure 16. Human Image Figure 17. Animal Image Figure 18. Global Recombinant DNA Vaccine Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 19. Global Recombinant DNA Vaccine Sales Market Share 2021 VS 2025 VS 2032 Figure 20. Global Recombinant DNA Vaccine Sales Market Share by Application (2021-2032) Figure 21. Global Recombinant DNA Vaccine Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 22. Global Recombinant DNA Vaccine Revenue Market Share 2021 VS 2025 VS 2032 Figure 23. Global Recombinant DNA Vaccine Revenue Market Share by Application (2021-2032) Figure 24. North America Recombinant DNA Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 25. North America Recombinant DNA Vaccine Sales Market Share by Country (2021-2032) Figure 26. U.S. Recombinant DNA Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 27. Canada Recombinant DNA Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 28. Mexico Recombinant DNA Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 29. Europe Recombinant DNA Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 30. Europe Recombinant DNA Vaccine Sales Market Share by Country (2021-2032) Figure 31. Germany Recombinant DNA Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 32. France Recombinant DNA Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 33. U.K. Recombinant DNA Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 34. Italy Recombinant DNA Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 35. Netherlands Recombinant DNA Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 36. Asia Pacific Recombinant DNA Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 37. Asia Pacific Recombinant DNA Vaccine Sales Market Share by Country (2021-2032) Figure 38. China Recombinant DNA Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 39. Japan Recombinant DNA Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 40. South Korea Recombinant DNA Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 41. Southeast Asia Recombinant DNA Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 42. India Recombinant DNA Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 43. Australia Recombinant DNA Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 44. South America, Middle East and Africa Recombinant DNA Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 45. South America, Middle East and Africa Recombinant DNA Vaccine Sales Market Share by Country (2021-2032) Figure 46. Brazil Recombinant DNA Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 47. South Africa Recombinant DNA Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 48. Saudi Arabia Recombinant DNA Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 49. Turkey Recombinant DNA Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 50. Argentina Recombinant DNA Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 51. UAE Recombinant DNA Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 52. Egypt Recombinant DNA Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 53. Chile Recombinant DNA Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 54. Global Recombinant DNA Vaccine Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 55. Global Recombinant DNA Vaccine Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 56. North America Recombinant DNA Vaccine Revenue (2021-2032) & (US$ Million) Figure 57. North America Recombinant DNA Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 58. Europe Recombinant DNA Vaccine Revenue (2021-2032) & (US$ Million) Figure 59. Europe Recombinant DNA Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 60. Asia-Pacific Recombinant DNA Vaccine Revenue (2021-2032) & (US$ Million) Figure 61. Asia-Pacific Recombinant DNA Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 62. South America, Middle East and Africa Recombinant DNA Vaccine Revenue (2021-2032) & (US$ Million) Figure 63. South America, Middle East and Africa Recombinant DNA Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. Recombinant DNA Vaccine Value Chain Figure 65. Manufacturing Cost Structure Figure 66. Recombinant DNA Vaccine Production Mode & Process Figure 67. Direct Comparison with Distribution Share Figure 68. Distributors Profiles Figure 69. Years Considered Figure 70. Research Process Figure 71. Key Executives Interviewed

Scope & coverage.

Types
  • Recombinant Protein Vaccine
  • Gene-Based Vaccine
Applications
  • Human
  • Animal
Companies covered
  • Boehringer-Ingelheim
  • Elanco
  • Indian Immunologicals
  • Plumbline Life Sciences
  • Zoties
  • GSK
  • Merck
  • Sanofi

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Recombinant DNA Vaccine Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Recombinant DNA Vaccine Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Recombinant DNA Vaccine Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Recombinant DNA Vaccine Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Recombinant DNA Vaccine Market Dynamics
  1. 2.1 Recombinant DNA Vaccine Industry Trends
  2. 2.2 Recombinant DNA Vaccine Industry Drivers
  3. 2.3 Recombinant DNA Vaccine Industry Opportunities and Challenges
  4. 2.4 Recombinant DNA Vaccine Industry Restraints
3 Recombinant DNA Vaccine Market by Manufacturers
  1. 3.1 Global Recombinant DNA Vaccine Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Recombinant DNA Vaccine Sales by Manufacturers (2021-2026)
  3. 3.3 Global Recombinant DNA Vaccine Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Recombinant DNA Vaccine Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Recombinant DNA Vaccine Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Recombinant DNA Vaccine Manufacturers, Product Type & Application
  7. 3.7 Global Recombinant DNA Vaccine Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Recombinant DNA Vaccine Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Recombinant DNA Vaccine Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Recombinant DNA Vaccine Tier 1, Tier 2, and Tier 3
4 Recombinant DNA Vaccine Market by Type
  1. 4.1 Recombinant DNA Vaccine Type Introduction
  2. 4.1.1 Recombinant Protein Vaccine
  3. 4.1.2 Gene-Based Vaccine
  4. 4.2 Global Recombinant DNA Vaccine Sales by Type
  5. 4.2.1 Global Recombinant DNA Vaccine Sales by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Recombinant DNA Vaccine Sales by Type (2021-2032)
  7. 4.2.3 Global Recombinant DNA Vaccine Sales Market Share by Type (2021-2032)
  8. 4.3 Global Recombinant DNA Vaccine Revenue by Type
  9. 4.3.1 Global Recombinant DNA Vaccine Revenue by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Recombinant DNA Vaccine Revenue by Type (2021-2032)
  11. 4.3.3 Global Recombinant DNA Vaccine Revenue Market Share by Type (2021-2032)
5 Recombinant DNA Vaccine Market by Application
  1. 5.1 Recombinant DNA Vaccine Application Introduction
  2. 5.1.1 Human
  3. 5.1.2 Animal
  4. 5.2 Global Recombinant DNA Vaccine Sales by Application
  5. 5.2.1 Global Recombinant DNA Vaccine Sales by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Recombinant DNA Vaccine Sales by Application (2021-2032)
  7. 5.2.3 Global Recombinant DNA Vaccine Sales Market Share by Application (2021-2032)
  8. 5.3 Global Recombinant DNA Vaccine Revenue by Application
  9. 5.3.1 Global Recombinant DNA Vaccine Revenue by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global Recombinant DNA Vaccine Revenue by Application (2021-2032)
  11. 5.3.3 Global Recombinant DNA Vaccine Revenue Market Share by Application (2021-2032)
6 Global Recombinant DNA Vaccine Sales by Region
  1. 6.1 Global Recombinant DNA Vaccine Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Recombinant DNA Vaccine Sales by Region (2021-2032)
  3. 6.2.1 Global Recombinant DNA Vaccine Sales by Region (2021-2026)
  4. 6.2.2 Global Recombinant DNA Vaccine Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Recombinant DNA Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Recombinant DNA Vaccine Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Recombinant DNA Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Recombinant DNA Vaccine Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Recombinant DNA Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Recombinant DNA Vaccine Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Recombinant DNA Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Recombinant DNA Vaccine Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Recombinant DNA Vaccine Revenue by Region
  1. 7.1 Global Recombinant DNA Vaccine Revenue by Region
  2. 7.1.1 Global Recombinant DNA Vaccine Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Recombinant DNA Vaccine Revenue by Region (2021-2026)
  4. 7.1.3 Global Recombinant DNA Vaccine Revenue by Region (2027-2032)
  5. 7.1.4 Global Recombinant DNA Vaccine Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Recombinant DNA Vaccine Revenue (2021-2032)
  8. 7.2.2 North America Recombinant DNA Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Recombinant DNA Vaccine Revenue (2021-2032)
  11. 7.3.2 Europe Recombinant DNA Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Recombinant DNA Vaccine Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Recombinant DNA Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Recombinant DNA Vaccine Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Recombinant DNA Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Boehringer-Ingelheim
  2. 8.1.1 Boehringer-Ingelheim Company Information
  3. 8.1.2 Boehringer-Ingelheim Business Overview
  4. 8.1.3 Boehringer-Ingelheim Recombinant DNA Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Boehringer-Ingelheim Recombinant DNA Vaccine Product Portfolio
  6. 8.1.5 Boehringer-Ingelheim Recent Developments
  7. 8.2 Elanco
  8. 8.2.1 Elanco Company Information
  9. 8.2.2 Elanco Business Overview
  10. 8.2.3 Elanco Recombinant DNA Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Elanco Recombinant DNA Vaccine Product Portfolio
  12. 8.2.5 Elanco Recent Developments
  13. 8.3 Indian Immunologicals
  14. 8.3.1 Indian Immunologicals Company Information
  15. 8.3.2 Indian Immunologicals Business Overview
  16. 8.3.3 Indian Immunologicals Recombinant DNA Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Indian Immunologicals Recombinant DNA Vaccine Product Portfolio
  18. 8.3.5 Indian Immunologicals Recent Developments
  19. 8.4 Plumbline Life Sciences
  20. 8.4.1 Plumbline Life Sciences Company Information
  21. 8.4.2 Plumbline Life Sciences Business Overview
  22. 8.4.3 Plumbline Life Sciences Recombinant DNA Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Plumbline Life Sciences Recombinant DNA Vaccine Product Portfolio
  24. 8.4.5 Plumbline Life Sciences Recent Developments
  25. 8.5 Zoties
  26. 8.5.1 Zoties Company Information
  27. 8.5.2 Zoties Business Overview
  28. 8.5.3 Zoties Recombinant DNA Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Zoties Recombinant DNA Vaccine Product Portfolio
  30. 8.5.5 Zoties Recent Developments
  31. 8.6 GSK
  32. 8.6.1 GSK Company Information
  33. 8.6.2 GSK Business Overview
  34. 8.6.3 GSK Recombinant DNA Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 GSK Recombinant DNA Vaccine Product Portfolio
  36. 8.6.5 GSK Recent Developments
  37. 8.7 Merck
  38. 8.7.1 Merck Company Information
  39. 8.7.2 Merck Business Overview
  40. 8.7.3 Merck Recombinant DNA Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Merck Recombinant DNA Vaccine Product Portfolio
  42. 8.7.5 Merck Recent Developments
  43. 8.8 Sanofi
  44. 8.8.1 Sanofi Company Information
  45. 8.8.2 Sanofi Business Overview
  46. 8.8.3 Sanofi Recombinant DNA Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Sanofi Recombinant DNA Vaccine Product Portfolio
  48. 8.8.5 Sanofi Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Recombinant DNA Vaccine Value Chain Analysis
  2. 9.1.1 Recombinant DNA Vaccine Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Recombinant DNA Vaccine Production Mode & Process
  6. 9.2 Recombinant DNA Vaccine Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Recombinant DNA Vaccine Distributors
  9. 9.2.3 Recombinant DNA Vaccine Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst